Irina Antonijevic
Chief Medical Officer Trace Neuroscience
Prior to joining Trace, Irina served as Chief Medical Officer at EveryONE Medicines, a precision medicine company targeting genetic variants causing fatal, neurodegenerative diseases. In this role, she was responsible for designing and implementing an individualized medicines platform focused on correcting uniquely rare neurogenetic mutations. She previously served as Chief Medical Officer and Head of R&D at Triplet Therapeutics, a company developing treatments for genetic conditions associated with expanded DNA nucleotide repeats. Earlier in her career, Irina held clinical and scientific roles at various pharmaceutical and biotechnology companies, including Wave Life Sciences, vasopharm GmbH, Sanofi Genzyme, Lundbeck, and Schering AG.
Irina is a board-certified physician trained in Psychiatry and Neurology at the Max Planck Institute of Psychiatry and was an adjunct faculty member at the University of Berlin. She holds an M.D. from the Max Planck Institute of Psychiatry and a Ph.D. from the University of Edinburgh
Seminars
- Reassessing the necessity of fully independent nonclinical toxicology packages for each candidate by examining shared chemistry, mechanism of action, and accumulated class safety data across oligonucleotide platforms
- Identifying the scientific commonalities that could justify a proportionate, risk-based regulatory approach, rather than repeating comprehensive packages where prior pharmacology and toxicology knowledge already exists
- Exploring practical strategies to align regulatory bodies around a platform framework, including early agency engagement, cross-program data integration, and clearer articulation of class-based evidence to enable streamlined, science-driven IND progression
- Discuss how a comprehensive, data-driven non-clinical development for ASOs can help optimize clinical dosing strategies, for a favorable safety profile, reducing toxicity risks and enabling a more efficient trial design
- Align non-clinical evidence with regional regulatory requirements to facilitate efficient clinical development and access to novel therapeutics for rare disease patients
- Utilize emerging clinical data and real-world insights to refine clinical trial designs and increase chance for early clinical proof-of-concept
